A TWO-PART PHASE 1, OPEN- LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE MULTIPLE DOSE PHARMACOKINETICS OF DANUGLIPRON FOLLOWING ORAL ADMINISTRATION AND THE EFFECTS OF STEADY-STATE DANUGLIPRON ON THE PHARMACOKINETICS OF SINGLE ORAL DOSE OF ATORVASTATIN AND ROSUVASTATIN IN OTHERWISE HEALTHY ADULT PARTICIPANTS WITH OVERWEIGHT OR OBESITY
Latest Information Update: 30 May 2025
At a glance
- Drugs Danuglipron (Primary) ; Atorvastatin; Rosuvastatin
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 14 Apr 2025 Status changed from active, no longer recruiting to discontinued.
- 28 Mar 2025 Planned End Date changed from 30 Apr 2025 to 19 Apr 2025.
- 28 Mar 2025 Planned primary completion date changed from 30 Apr 2025 to 19 Apr 2025.